- Share on:
- Bio-rad Twitter
- Bio-rad Facebook
- Bio-rad LinkedIn
Rapid and Sensitive Mycoplasma Detection Using ddPCR™ Technology
Contamination in the cells used to produce biotherapeutics can derail development. Unfortunately, the most common contaminant of cell lines, Mycoplasma, is both one of the hardest to detect and one of the hardest to get rid of. Early Mycoplasma detection with rapid, sensitive, and specific ddPCR technology can save significant amounts of lost time and money.
Read this article to learn:
- Limitations of traditional methods to detect Mycoplasma, including broth cultures, staining, and qPCR
- How to use ddPCR technology to achieve species-specific Mycoplasma detection at concentrations as low as one colony forming unit/ml of broth culture
- Why using ddPCR technology to detect contamination can ensure safer, higher quality therapeutics
Download the Article
Share a little information with us to access the entire article now.
Thank you for your interest in ! Access the article here.
View ArticleContent you'll also find interesting
Thank you for submitting the form.
Recommended Features
-
Image
Ensuring Safety Throughout the Antibody Development Process
We look into the importance of demonstrating safety throughout antibody development, manufacturing, and QC. Find tools and processes that address challenges.
-
Image
Mycoplasma Detection during Biotherapeutic Development
Learn how ddPCR technology is a reliable, sensitive, and rapid approach for detecting Mycoplasma contamination and ensuring the safety of biotherapeutics.
-
Image
Biosimilar Production with IEX and Mixed-Mode Resins
Learn how process economics is improved more than fourfold for biosimilar production with an ion exchange and mixed-mode purification workflow.